Aurinia Pharmaceuticals (AUPH)
NASDAQ:AUPH
Want to see AUPH full AI Analyst Report?
Total Valuation
Aurinia Pharmaceuticals has a market cap or net worth of $1.97B. The enterprise value is $1.99B.
Market Cap$1.97B
Enterprise Value$1.99B
Share Statistics
Aurinia Pharmaceuticals has 128,601,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding128,601,670
Owned by Insiders11.64%
Owned by Institutions18.90%
Financial Efficiency
Aurinia Pharmaceuticals’s return on equity (ROE) is 0.49 and return on invested capital (ROIC) is 15.53%.
Return on Equity (ROE)0.49
Return on Assets (ROA)0.38
Return on Invested Capital (ROIC)15.53%
Return on Capital Employed (ROCE)0.16
Revenue Per Employee2.18M
Profits Per Employee2.21M
Employee Count130
Asset Turnover0.38
Inventory Turnover0.71
Valuation Ratios
The current PE Ratio of Aurinia Pharmaceuticals is 14.3. Aurinia Pharmaceuticals’s PEG ratio is 0.00142.
PE Ratio14.3
PS Ratio7.57
PB Ratio3.69
Price to Fair Value3.69
Price to FCF15.83
Price to Operating Cash Flow12.20
PEG Ratio0.00142
Income Statement
In the last 12 months, Aurinia Pharmaceuticals had revenue of 283.06M and earned 287.20M in profits. Earnings per share was 2.14.
Revenue283.06M
Gross Profit250.39M
Operating Income104.91M
Pretax Income114.16M
Net Income287.20M
EBITDA127.76M
Earnings Per Share (EPS)2.14
Cash Flow
In the last 12 months, operating cash flow was 165.82M and capital expenditures -271.76K, giving a free cash flow of 165.55M billion.
Operating Cash Flow165.82M
Free Cash Flow165.55M
Free Cash Flow per Share1.29
Dividends & Yields
Aurinia Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.46
52-Week Price Change89.34%
50-Day Moving Average14.75
200-Day Moving Average13.40
Relative Strength Index (RSI)62.28
Average Volume (3m)1.07M
Important Dates
Aurinia Pharmaceuticals upcoming earnings date is Jul 30, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Aurinia Pharmaceuticals as a current ratio of 5.25, with Debt / Equity ratio of 12.09%
Current Ratio5.25
Quick Ratio4.76
Debt to Market Cap0.03
Net Debt to EBITDA-0.04
Interest Coverage Ratio24.23
Taxes
In the past 12 months, Aurinia Pharmaceuticals has paid -173.04M in taxes.
Income Tax-173.04M
Effective Tax Rate-1.52
Enterprise Valuation
Aurinia Pharmaceuticals EV to EBITDA ratio is 16.73, with an EV/FCF ratio of 15.79.
EV to Sales7.55
EV to EBITDA16.73
EV to Free Cash Flow15.79
EV to Operating Cash Flow15.76
Balance Sheet
Aurinia Pharmaceuticals has $378.78M in cash and marketable securities with $68.64M in debt, giving a net cash position of $310.14M billion.
Cash & Marketable Securities$378.78M
Total Debt$68.64M
Net Cash$310.14M
Net Cash Per Share$2.41
Tangible Book Value Per Share$4.30
Margins
Gross margin is 89.74%, with operating margin of 37.06%, and net profit margin of 101.47%.
Gross Margin89.74%
Operating Margin37.06%
Pretax Margin40.33%
Net Profit Margin101.47%
EBITDA Margin45.14%
EBIT Margin41.86%
Analyst Forecast
The average price target for Aurinia Pharmaceuticals is $16.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$16.00
Price Target Upside-0.31% Downside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast20.62%
EPS Growth Forecast696.05%